Apixaban more advanced than enoxaparin in reducing venous thromboembolism altogether knee replacement surgery patients Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Business and Pfizer Inc. , was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients going through elective total knee replacing surgery, according today in The Lancet to the ADVANCE-2 research results published consult your doctor click here . The study results also showed numerically lower prices of major and relevant non-main bleeding in sufferers treated with apixaban clinically compared with those treated with enoxaparin.


Overweight people often get stigmatized as lazy and lacking self-discipline, lead writer Aaron Blaisdell said. We interpret our results as suggesting that the idea frequently portrayed in the mass media that people become fat because they’re lazy is incorrect. Our data suggest that diet-induced obesity is a cause, than an effect rather, of laziness. Either the processed diet causes exhaustion or the diet causes obesity highly, which causes fatigue. Impaired inspiration The researchers fed 32 female rats either a standard diet composed mostly of unprocessed foods or a diet composed mostly of prepared, sugary foods.